177 related articles for article (PubMed ID: 35924546)
1. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
[TBL] [Abstract][Full Text] [Related]
2. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
Ann Hematol; 2024 Mar; ():. PubMed ID: 38438627
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
4. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
5. Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P; Mascarenhas J; Bose P; Hobbs G; Yacoub A; Palmer JM; Gerds AT; Masarova L; Kuykendall AT; Rampal RK; Mesa R; Verstovsek S
Ther Adv Hematol; 2024; 15():20406207241229588. PubMed ID: 38380373
[TBL] [Abstract][Full Text] [Related]
6. A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy.
Bang SY; Lee SE
Hematol Rep; 2023 Mar; 15(1):172-179. PubMed ID: 36975731
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
[No Abstract] [Full Text] [Related]
12. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á; Pinczés LI; Egyed M
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
[TBL] [Abstract][Full Text] [Related]
13. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
Liu WD; Hou HA; Li KJ; Qin A; Tsai CY; Sheng WH
Adv Ther; 2024 Feb; 41(2):847-856. PubMed ID: 38010606
[TBL] [Abstract][Full Text] [Related]
14. [Myeloproliferative neoplasms: recent progresses in therapy].
Kamiunten A; Shide K; Shimoda K
Rinsho Ketsueki; 2018; 59(6):741-746. PubMed ID: 29973454
[TBL] [Abstract][Full Text] [Related]
15. Ropeginterferon alfa-2 b for the therapy of polycythemia vera.
Červinek L
Vnitr Lek; 2020; 66(5):309-313. PubMed ID: 32942868
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Gugliotta L; Besses C; Griesshammer M; Harrison C; Kiladjian JJ; Coll R; Smith J; Abhyankar B; Birgegård G
Haematologica; 2014 Apr; 99(4):679-87. PubMed ID: 24334294
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
18. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
20. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
